ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer
Open Access
- 13 January 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 12 (5), 872-877
- https://doi.org/10.1016/j.jtho.2017.01.004
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (5R01CA164273)
This publication has 23 references indexed in Scilit:
- Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic AlgorithmJournal of Thoracic Oncology, 2013
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1New England Journal of Medicine, 2013
- The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaAnnals Of Oncology, 2013
- ROS1-Rearranged Lung CancerThe American Journal of Surgical Pathology, 2013
- Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung CancerJournal of Thoracic Oncology, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel SequencingCancer Discovery, 2012
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007